Combination Therapy with Upadacitinib and Acitretin in Recalcitrant Darier Disease: A Case Report
DOI:
https://doi.org/10.2340/actadv.v106.adv-2026-0662Keywords:
upadacitinib, JAK inhibitor, refractory, combination therapy, acitretin, Darier’s diseaseDownloads
References
Stefani C, de Gemmis P, Cattelan P, Tibaudo L, Stagni C, De Sensi E, et al. Expanding the spectrum of Darier Disease variants: 13 novel ATP2A2 genetic variations discovered in an Italian retrospective analysis. Gene 2026; 990: 150071. DOI: https://doi.org/10.1016/j.gene.2026.150071
Zhou MH, Stirrat TP, Edminister JR, Elston DM, Jorizzo J, Motaparthi K, et al. Acantholytic disorders: Update on pathophysiology, diagnosis, and management. J Am Acad Dermatol 2026; 95: 138–147. DOI: https://doi.org/10.1016/j.jaad.2026.02.074
Dessinioti C, Katsambas A. Vitamins and the skin: Vitamin A and retinoids in dermatology. Clin Dermatol 2026; 44: 212–222. DOI: https://doi.org/10.1016/j.clindermatol.2026.02.005
Beyens A, Speeckaert R. Transient responses to biologic therapy in Darier disease: consider the role of dysbiosis-driven inflammation. J Eur Acad Dermatol Venereol 2026; 40: 351–352. DOI: https://doi.org/10.1111/jdv.70283
Wu Z, Lian G, He L, Hu P, Guo Y, Su Z. Targeting JAK-STAT signaling for autoimmune diseases: current understanding, clinical advances, and emerging directions. Immunol Cell Biol 2026; 104: 172–191. DOI: https://doi.org/10.1111/imcb.70078
Behrangi E, Dehghani A, Zeinali R, Amiri S. Darier’s disease successfully treated with tofacitinib: a case report. Case Rep Dermatol 2025; 17: 574–579. DOI: https://doi.org/10.1159/000548764
Busto Leis JM, Negre GS, Mayor Ibarguren AP, Pinto PH. Response of Darier disease following treatment with baricitinib. JAMA Dermatol 2022; 158: 699–701. DOI: https://doi.org/10.1001/jamadermatol.2022.1021
Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O’Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov 2017; 16: 843–862. DOI: https://doi.org/10.1038/nrd.2017.201
Parmentier JM, Voss J, Graff C, Schwartz A, Argiriadi M, Friedman M, et al. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatol 2018; 2: 23. DOI: https://doi.org/10.1186/s41927-018-0031-x
Sun Z, Bao L. A case of Darier disease with p.N767S mutation in ATP2A2 successfully treated with upadacitinib. Am J Dermatopathol 2026; 48: 410–411. DOI: https://doi.org/10.1097/DAD.0000000000003242
Published
How to Cite
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
